RxDoctor Payments Data

Jeremy Gutwein, MD

Gastroenterology · Bronx, NYNPI 1235279738

Payments from drug & device makers

$24,821in general payments, 2019–2025

Across 864 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Capsovision, Inc.$11K
  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • Madrigal Pharmaceuticals$529
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$11,38346%
  • Speaking & faculty fees$200%
  • Grants$200%
  • Food & beverage$13,21053%
  • Education$1871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,821 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$35,707
Medicare patients
95
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab37$1,009,542
LinzessLinaclotide154$128,720
XifaxanRifaximin31$100,358
Humira PenAdalimumab12$79,310
CreonLipase/Protease/Amylase27$54,589
VemlidyTenofovir Alafenamide12$16,190
Mesalamine16$10,172
Dexlansoprazole DrDexlansoprazole30$7,209
TrulancePlecanatide11$5,760
Lubiprostone30$5,053
Omeprazole277$3,723
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C15$2,060
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl93$1,226
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates23$1,214
Esomeprazole Magnesium19$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,063$1,009,54237 claims
AbbVieLinzess, Creon$3,609$183,309181 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$2,355$108,17857 claims
GileadVemlidy$344$16,19012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →